您好,欢迎访问中山大学肿瘤防治中心官方网站!
内部网 职工邮箱 图书馆 OA系统 医生门户 English
院士风采 首席专家 临床专家 科研学者 客座教授 人才名录 护理专家
首页
  • 李宇红

    职务:内科二区区长
    职称:主任医师、博士生导师
    专长:擅长消化道肿瘤(食管癌、胃癌、肠癌、胰腺癌、胆管癌、胃肠胰神经内分泌肿瘤等)和鼻咽癌的内科治疗(化学治疗、靶向治疗)。
    1.姓名:李宇红 
    2.职称:主任医师、博士生导师
    3.专长:擅长消化道肿瘤(肠癌、胃癌、食管癌、胰腺癌、胆管癌、胃肠胰神经内分泌肿瘤等)的化疗和分子靶向药物治疗
    4.出诊时间:周二上午 

    5.学术兼职:
    广东抗癌协会分子靶向与个体化治疗专业委员会副主任委员(侯任主委员)
    广东省医学会消化道肿瘤分会副主任委员
    广东省抗癌协会食管癌专业委员会副主任委员
    广东省抗癌协会大肠癌专业委员会常务委
    中国抗癌协会分子靶向专业委员会常委
    中国大肠癌专业委员会化疗学组委员
    中国抗癌协会胰腺癌专业委员会神经内分泌肿瘤学组委员

    6.个人简介: 
      从事肿瘤内科临床工作20余年,尤其在消化道肿瘤(肠癌、胃癌、食管癌、胰腺癌、胆管癌、胃肠胰神经内分泌肿瘤等)治疗方面有较丰富的经验。近年来,主要专注于消化道肿瘤的临床和转化研究工作。2007年和2009年分别赴法国Paul Brouss医院和美国Mayo Clinic短期进修消化道肿瘤治疗。主持和参加国家自然科学基金、广东省自然科学基金、广州市协同创新重大专项等多项基金项目。公开发表论文100余篇,其中以第一作者或通讯作者在《Clinical Cancer Research》, 《Annals of Oncology》, 《Cancer》等杂志发表SCI论文近30篇。为“结直肠癌的个体化治疗研究和应用”项目的重要完成人之一,该项目荣获2016年国家科技进步二等奖,2015年中华科技奖一等奖、2015年广东省科技进步一等奖。
    1.姓名:李宇红
    2.职称:主任医师、博士生导师
    3.专长:擅长消化道肿瘤(肠癌、胃癌、食管癌、胰腺癌、胆管癌、胃肠胰神经内分泌肿瘤等)的化疗和分子靶向药物治疗
    4.出诊时间:周二上午 

    5.学术兼职:
    广东抗癌协会分子靶向与个体化治疗专业委员会副主任委员(侯任主委员)
    广东省医学会消化道肿瘤分会副主任委员
    广东省抗癌协会食管癌专业委员会副主任委员
    广东省抗癌协会大肠癌专业委员会常务委
    中国抗癌协会分子靶向专业委员会常委
    中国大肠癌专业委员会化疗学组委员
    中国抗癌协会胰腺癌专业委员会神经内分泌肿瘤学组委员

    6.个人简介: 
      从事肿瘤内科临床工作20余年,尤其在消化道肿瘤(肠癌、胃癌、食管癌、胰腺癌、胆管癌、胃肠胰神经内分泌肿瘤等)治疗方面有较丰富的经验。近年来,主要专注于消化道肿瘤的临床和转化研究工作。2007年和2009年分别赴法国Paul Brouss医院和美国Mayo Clinic短期进修消化道肿瘤治疗。主持和参加国家自然科学基金、广东省自然科学基金、广州市协同创新重大专项等多项基金项目。公开发表论文100余篇,其中以第一作者或通讯作者在《Clinical Cancer Research》, 《Annals of Oncology》, 《Cancer》等杂志发表SCI论文近30篇。为“结直肠癌的个体化治疗研究和应用”项目的重要完成人之一,该项目荣获2016年国家科技进步二等奖,2015年中华科技奖一等奖、2015年广东省科技进步一等奖。

    7.代表性文章:
    1. Li YH, Wang F, et al. EGFR FISH Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer patients. Clin Cancer Res.2011: 15; 17(2):382.
    2. Luo HY, Li YH, (contribute equally), et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann of Oncol.2016: 27: 1074.
    3. Wang FH, Li YH (Corresponds), et al. Efficacy and safety of recombinant human  lymphotoxin-alpha derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial. Cancer. 2017, 123: 3986.
    4. An X, Li YH (Corresponds), et al.. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. Cancer. 2014 Mar 1; 120(5):675.
    5. An X, Li YH (Corresponds), et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011; 15; 117(16):3750.
    6. Li YH, He YF, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006, 15; 106(6):1320
    7. Wang Y, Li YH (Corresponds), et al. The Immunoscore system predicts pro gnosis after liver metastasectomy in colorectal cancer liver metastases. Cancer Immunol Immunother.  2017 Online. 
    8. Wang Y, Li YH (Corresponds), et al.. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases .Chin J Cancer. 2017, 36: 78.
    9. Wang Y, Li YH (Corresponds), et al. The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile? J Cancer .2017:8: 1179.
    10. Wang Y, Li YH (Corresponds), et al.. Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget.  2017:7: 57290.
    11. Zhang F, Li YH (Corresponds), et al. Fibrinogen promotes malignant biological tumor behavior involving epithelial-mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma. J Cancer s Res Clin  Oncol. 2017:143(12):2413.
    12. Zhang F, Li YH (Corresponds), et al. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.  Dis Esophagus.2017; 30: 1.
    13. Cong Li, Li YH (Corresponds), et al. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5‑fluorouracil and leucovorin (m‑FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Cancer Chemother Pharmacol.2014: 74:1079.
    14. Zhang L, Li YH (Corresponds), et al. MGMT in colorectal cancer: a promising component of personalized treatment. Tumour Biol. 2016 Mar 22.
    15. Li YH, Qiu MZ, et al. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015; (33):35107.  
    16. Wang Y, Li YH (Corresponds), et al. Effect of Raf kinase inhibitor protein expression on malignant biological behavior and progression of colorectal cancer. Oncol Rep. 2015; 34(4):2106.  
    17. Jiang YX, Li YH (Corresponds), et al. Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. Int J Clin Exp Med. 2015; 8(6):8472.
    18. An X, Li YH (Corresponds), et al. Serum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinoma. PLoS One. 2013 May 14; 8(5):e63458. 
    19. Chen C, Li YH (Corresponds), et al. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2013 Aug; 72(2):315.
    20. Chen C, Li YH (Corresponds), et al.Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma. Cancer Chemotherapy Pharmacol. 2013 Feb; 71(2):371.
    21. Chen C, Li YH (Corresponds), et al. Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum- based chemotherapy. Oral Oncol. 2012 Nov; 48(11):1146. 
    22. An X, Li YH (Corresponds), et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumor Biol. 2011; 32(2):317.
    23. Wang FH, Li YH (Corresponds), et al. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Am J Clin Oncol. 2011; 34(4):401.
    24. Li YH, Luo HY, et al. Phase II study of capecitabine plus oxaliplatin(XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2010; 136(4):503.
    25. An X, Li YH (Corresponds), et al. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy. Biomarkers. 2010; 15(3):243. 
    26. Li YH, Hu CF, et al. Elevated Expressions of Survivin and VEGF Protein are Strong Independent Predictors of Survival in Advanced Nasopharyngeal Carcinoma. J Transl Med. 2008; 3; 6(1):1.
    27. Li YH, Wang FH, et al. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2008; 62(3):539. 
    28. He YF, Li YH (Corresponds) et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol. 2008; 87(6):481.


    更新日期:2018年1月31日
访客通道
员工通道
关注肿瘤医院
留言建议 ×